Company news
Regen Biopharma, Inc. (OTC:RGBP) news
Regen Biopharma, Inc. news releases on 6ix. Latest, Dec 7, 2016: Regen BioPharma, Inc. Discusses a Recent Important Discovery of NR2F6 in Human Cervical Cancer
Press releases — page 2
Regen BioPharma, Inc. Discusses a Recent Important Discovery of NR2F6 in Human Cervical Cancer
December 7, 2016
Regen BioPharma's Chief Scientific Officer Harry Lander Provides Clarity on the Process of Small Molecule Development for Cancer and Autoimmune Diseases
November 16, 2016
Regen BioPharma, Inc. Discusses Next Steps in its NR2F6 Small Molecule Program
October 31, 2016
Pan Am Cancer Treatment Center Provides Final HemaXellerate Clinical Data to Regen BioPharma, Inc. for treatment of Bone Marrow Suppression Study
October 24, 2016
Entest BioMedical's Zander Therapeutics Unit Files Composition of Matter Patent on NR2F6 Modulating Small Molecules in Canine and Feline Applications
October 19, 2016
Regen BioPharma, Inc. Announces the Appointment of Xiaojing Ma, PhD as the Company's New Senior Research Advisor
September 29, 2016
Regen BioPharma Responds to FDA Comments on Its Application for Orphan Drug Designation on its Aplastic Anemia Therapy
September 22, 2016
Regen BioPharma, Inc. Receives Positive Data From Preclinical Studies of Its Small Molecule NR2F6 Modulators
September 20, 2016
Regen BioPharma, Inc. Responds to FDA on dCellVax Gene-Silenced Breast Cancer Immunotherapy
September 14, 2016
Regen BioPharma, Inc. Updates Shareholders on Status of Non-Dilutive Funding Opportunities
August 25, 2016
Regen BioPharma, Inc. Receives New Preliminary HemaXellerate Clinical Data on Bone Marrow Suppression from Pan Am Cancer Treatment Center
August 16, 2016
Regen BioPharma, Inc. Files Composition of Matter Patent Application on NR2F6 Modulating Small Molecules
July 27, 2016
Regen BioPharma President Harry Lander Provides Mid-year Update on Company's Progress and Developments
July 13, 2016
Regen BioPharma, Inc. Enters Into Open Innovation Drug Discovery Program Agreement with Eli Lilly and Company
June 30, 2016
Regen BioPharma, Inc.'s CEO Discusses and Clarifies the Potential of the NR2F6 Activator Program
June 16, 2016
Regen BioPharma, Inc.'s Small Molecule Drug Screening Program Uncovers Activators of NR2F6
June 14, 2016
Regen BioPharma, Inc. Retains Objective Capital Partners, LLC to Explore Non-Dilutive Funding Opportunities
June 7, 2016
Regen BioPharma, Inc. Discusses Its Major Small Molecule Drug Screening Program Targeting Immune Checkpoint NR2F6
June 2, 2016
Regen BioPharma, Inc. Uplisted to Trade Publicly on OTCQB
June 1, 2016
OTC Markets Group Welcomes Newly Verified OTCQB Companies – May 31
May 31, 2016
Regen BioPharma, Inc. Files Application to Trade Publicly on OTCQB
May 24, 2016
RGBP - announced a share distribution of Series A Preferred Shares with a record date of 03/10/2015. RGBP will not be quoted ex-dividend
March 6, 2015